Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

Kyle, 2016, Regarding obesity as a disease: evolving policies and their implications, Endocrinol Metab Clin North Am, 45, 511, 10.1016/j.ecl.2016.04.004 Garvey, 2016, American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity: executive summary, Endocr Pract, 22, 842, 10.4158/EP161356.ESGL 1997 Bray, 2016, Management of obesity, Lancet, 387, 1947, 10.1016/S0140-6736(16)00271-3 Cawley, 2012, The medical care costs of obesity: an instrumental variables approach, J Health Econ, 31, 219, 10.1016/j.jhealeco.2011.10.003 Bray Mertens, 2000, Overweight, obesity, and blood pressure: the effects of modest weight reduction, Obes Res, 8, 270, 10.1038/oby.2000.32 Warkentin, 2014, The effect of weight loss on health-related quality of life: systematic review and meta-analysis of randomized trials, Obes Rev, 15, 169, 10.1111/obr.12113 Mann, 2007, Medicare's search for effective obesity treatments: diets are not the answer, Am Psychol, 62, 220, 10.1037/0003-066X.62.3.220 Dombrowski, 2014, Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials, BMJ, 348, g2646, 10.1136/bmj.g2646 Onakpoya, 2016, Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review, BMC Med, 14, 191, 10.1186/s12916-016-0735-y Flint, 1998, Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans, J Clin Invest, 101, 515, 10.1172/JCI990 Doyle, 2007, Mechanisms of action of glucagon-like peptide 1 in the pancreas, Pharmacol Ther, 113, 546, 10.1016/j.pharmthera.2006.11.007 Sorli, 2017, Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial, Lancet Diabetes Endocrinol, 5, 251, 10.1016/S2213-8587(17)30013-X Ahrén, 2017, Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial, Lancet Diabetes Endocrinol, 5, 341, 10.1016/S2213-8587(17)30092-X Aroda, 2017, Lancet Diabetes Endocrinol, 5, 355, 10.1016/S2213-8587(17)30085-2 Ware, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med Care, 30, 473, 10.1097/00005650-199206000-00002 Seaquist, 2013, Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society, Diabetes Care, 36, 1384, 10.2337/dc12-2480 Pi-Sunyer, 2015, A randomized, controlled trial of 3.0 mg of liraglutide in weight management, N Engl J Med, 373, 11, 10.1056/NEJMoa1411892 Rubin, 1987 Dunnett, 1955, A multiple comparison procedure for comparing several treatments with a control, J Am Stat Assoc, 50, 1096, 10.1080/01621459.1955.10501294 Dunnett, 1964, New tables for multiple comparisons with a control, Biometrics, 20, 481, 10.2307/2528490 Banks, 2013, Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus, Gut, 62, 102, 10.1136/gutjnl-2012-302779 Blundell, 2017, Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity, Diabetes Obes Metab, 19, 1242, 10.1111/dom.12932 Ard, 2016, Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials, Diabetes Obes Metab, 18, 430, 10.1111/dom.12632 le Roux, 2017, 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial, Lancet, 389, 1399, 10.1016/S0140-6736(17)30069-7 Fidler, 2011, A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial, J Clin Endocrinol Metab, 96, 3067, 10.1210/jc.2011-1256 Apovian, 2013, A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II), Obesity, 21, 935, 10.1002/oby.20309